A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)

ACTIVE NOT RECRUITING

NCT06577935

PHASE2

Sponsor: Angitia Biopharmaceuticals

Summary

The primary objective of this study is to determine the effect of treatment with AGA2118 versus placebo at Month 12 on lumbar spine bone mineral density (BMD) in postmenopausal women with low bone mass.

Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Safety, Tolerability and Efficacy of AGA2118 in Postmenopausal Women With Low Bone Mineral Density

Key Details

Gender

FEMALE

Age Range

55 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

379

Start Date

2024-10-31

Completion Date

2028-03

Last Updated

2026-02-10

Healthy Volunteers

No

Conditions

Postmenopausal Osteoporosis

Interventions

DRUG

AGA2118

Subcutaneous injection

OTHER

Placebo

Subcutaneous injection

Locations (23)

University of Alabama at Birmingham

Birmingham, Alabama, United States

Center for Advanced Research & Education

Gainesville, Georgia, United States

NM Clinical Research & Osteoporosis Center, Inc.

Albuquerque, New Mexico, United States

Altoona Center for Clinical Research

Duncansville, Pennsylvania, United States

Puget Sound Osteoporosis Center

Burien, Washington, United States

Centro Médico Dra Laura Maffei e Investigación Cliínica Aplicada